Stefanoudakis Dimitrios, Frountzas Maximos, Schizas Dimitrios, Michalopoulos Nikolaos V, Drakaki Alexandra, Toutouzas Konstantinos G
First Propaedeutic Department of Surgery, Hippocration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177.
The present review demonstrates the major tumor suppressor genes, including TP53, CDKN2A and SMAD4, associated with pancreatic cancer. Each gene's role, prevalence and impact on tumor development and progression are analyzed, focusing on the intricate molecular landscape of pancreatic cancer. In addition, this review underscores the prognostic significance of specific mutations, such as loss of TP53, and explores some potential targeted therapies tailored to these molecular signatures. The findings highlight the importance of genomic analyses for risk assessment, early detection and the design of personalized treatment approaches in pancreatic cancer. Overall, this review provides a comprehensive analysis of the molecular intricacies of pancreatic tumors, paving the way for more effective and tailored therapeutic interventions.
本综述展示了与胰腺癌相关的主要肿瘤抑制基因，包括TP53、CDKN2A和SMAD4。分析了每个基因在肿瘤发生和进展中的作用、发生率及影响，重点关注胰腺癌复杂的分子格局。此外，本综述强调了特定突变（如TP53缺失）的预后意义，并探索了一些针对这些分子特征的潜在靶向治疗方法。研究结果突出了基因组分析在胰腺癌风险评估、早期检测及个性化治疗方案设计中的重要性。总体而言，本综述对胰腺肿瘤的分子复杂性进行了全面分析，为更有效、更具针对性的治疗干预铺平了道路。
